Complementary Therapies Availability Poses Threat To Controlled Liver Trials
This article was originally published in The Tan Sheet
Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.
You may also be interested in...
The creation of pilot surveillance programs to track the role of herbals and dietary supplements in unexplained episodes of hepatotoxicity was proposed by a Centers for Disease Control & Prevention epidemiologist at a symposium on complementary and alternative medicine in chronic liver disease. The symposium was held at the National Institutes of Health in Bethesda, Md. Aug. 24.
NIH clinical trial studying St. John's wort's efficacy in treating depression has enrolled about one-fourth of the expected 330 patients. The study, led by principle investigator Jonathan Davidson, MD, Duke University, is being funded by NIH's National Center for Complementary & Alternative Medicine, National Institute of Mental Health and Office of Dietary Supplements. Recruitment was delayed due to a problem with Duke's Review Board research review procedures ("The Tan Sheet" May 17, In Brief)
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC